AstraZeneca to Buy Ardea Biosciences for $1.26 Billion

April 23, 2012
AstraZeneca will acquire gout treatment Lesinurad as part of the deal.

Anglo-Swedish drugs giant AstraZeneca PLC (IW 1000/119) on Monday said it had agreed to buy U.S. biotechnology company Ardea Biosciences in a deal worth around $1.26 billion.

"AstraZeneca and Ardea Biosciences, Inc. today announced that they have entered into a definitive merger agreement, pursuant to which AstraZeneca will acquire Ardea, a San Diego, California-based biotechnology company focused on the development of small-molecule therapeutics," a statement said. "Under the terms of the agreement, AstraZeneca will acquire Ardea for $32 per share which represents a total cash value of approximately $1.26 billion."

AstraZeneca added that the price represents a premium of 54% based on Ardea's closing share price last Friday.

Under the deal, AstraZeneca will acquire Lesinurad, a product still in development for the treatment of gout but which it believes has great potential.

"The Ardea team has done a great job developing Lesinurad along with a promising next-generation gout program," AstraZeneca chief executive David Brennan said in the statement.

"These compounds have real potential to benefit patients."

AstraZeneca, which earlier this year announced plans to cut 7,300 jobs by 2014, is seeking new opportunities amid a predicted drop in group earnings this year as patents on some of its key drugs expire.

Copyright Agence France-Presse, 2012

Sponsored Recommendations

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!